Relay Therapeutics, Inc. (RLAY) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • High cash burn • Minimal revenue RLAY has a fortress-like balance sheet with very low leverage and ample liquid assets but is burning cash heavily with negligible revenue, large losses, and richly stretched valuation that create acute operational risk until revenues and margins improve.
Price Behavior
Key Price Behavior Insights: • Strong momentum • Extended premium • Key failure point Support Level: $12.45–$12.54; $9.35–$10.77 (anchor $10.55) Resistance Level: $15.00 Strong short-term uptrend (≈41.6% rise to $14.94) but trading ~35% above last month's SMA (~$11.10), so the move is extended and vulnerable to mean reversion; failure to clear recent high ~$15.00 would be bearish.
Sentiment & News
Key News Insights: • Zovegalisib efficacy • Stock surge • Mixed ownership Relay Therapeutics reported encouraging Phase 1/2 zovegalisib efficacy with FDA Breakthrough designation and upcoming vascular‑anomalies data, fueling a stock rally and analyst “Moderate Buy” consensus amid mixed institutional trades.
AI Summary
RLAY has shifted from a speculative platform story to a de‑risked, single‑asset, catalyst‑driven bet—zovegalisib's Breakthrough designation, supportive Phase 1/2 PFS and underway Phase 3 mean near‑term upside hinges on trial readouts while its ~$555M cash cushion lowers immediate financing risk but watch enrollment, safety signals and burn rates closely since any setback or timeline slip would likely force dilutive financing and sharp valuation compression.
Description
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental methods to improve small-molecule discovery, initially concentrating on targeted oncology and genetic disease indications. Its clinical programs include an FGFR2 inhibitor (RLY-4008) in first-in-human testing, a mutant PI3Ka inhibitor program (RLY-2608), and an SHP2 inhibitor (RLY-1971) in Phase 1, and the company maintains research collaborations with D. E. Shaw Research for protein-motion modeling and with Genentech for development and commercialization of RLY-1971. Founded in 2015, Relay Therapeutics is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | RLAY | Relay Therapeutics, Inc. | Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events. | Active | +1.3% |